Clinical Trial

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

Name: BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer — clinical trial record (NCT06085742)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BRE-08

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2023-10-09; most recent amendment 2025-12-17.

Trial Details

NCT Number	NCT06085742
Lead Sponsor	University of Illinois at Chicago
Conditions	Breast Cancer
Enrollment	25 participants
Start Date	2023-11-22
Primary Completion	2034-09 (estimated)
Study Completion	2034-09 (estimated)
Updated on ClinicalTrials.gov	2025-12-19